Results 111 to 120 of about 17,457 (176)

The Prevalence, Mechanisms, and Clinical Significance of Inferior Vena Cava Compression in Autosomal Dominant Polycystic Kidney Disease: A Multicenter Retrospective Cohort Study Based on TriNetX. [PDF]

Medicina (Kaunas)
Matarneh A, Matarneh B, Akkari A, Sardar S, Salameh O, Verma N, Ghahramani N.   +6 more
europepmc   +1 more source

RETRACTED: Kebede et al. Determinants of Disease Progression in Autosomal Dominant Polycystic Kidney Disease. <i>J. Pers. Med.</i> 2024, <i>14</i>, 936. [PDF]

J Pers Med
Kebede MA, Mengistu YT, Loge BY, Eshetu MA, Shash EP, Wirtu AT, Gemechu JM.   +6 more
europepmc   +1 more source

Quantitative dynamic contrast-enhanced magnetic resonance imaging for renal perfusion measurement in autosomal dominant polycystic kidney disease. [PDF]

Quant Imaging Med Surg
Onuoha EE, Holland MD, Krishnan C, Mrug M, Kim H.   +4 more
europepmc   +1 more source

The PKD Daily: Development and Content Validation of a Hybrid Diary for Tracking Urinary Events in Adults with Autosomal Dominant Polycystic Kidney Disease (ADPKD). [PDF]

Adv Ther
O'Connor M, Broderick L, Waldman LT, Costa E, Carty M, Nunna S, Oberdhan D.   +6 more
europepmc   +1 more source

Effect of tolvaptan on the prognosis of patients with rapidly progressive autosomal dominant polycystic kidney disease: a prospective open-label study. [PDF]

Front Med (Lausanne)
Zhou L, Li W.
europepmc   +1 more source

Phenotype of autosomal dominant Alport syndrome with a likely pathogenic heterozygous variant in the COL4A3 gene (Gly366Arg) and incidental teratozoospermia: A case report. [PDF]

An Sist Sanit Navar
Martín Moreno V, Martín Fernández A, García Mateos A, Hurtado Gallar J, Angulo García C, Sánchez-Redondo Mayordomo R.   +5 more
europepmc   +1 more source

Obturator hernia in autosomal dominant polycystic kidney disease

Kidney Research and Clinical Practice, 2018
Jong Hwan Jung, Ju Hung Song, Seon-Ho Ahn   +2 more
doaj   +1 more source

Association of 24-hour urinary parameters with renal function and other comorbidities in autosomal dominant polycystic kidney disease. [PDF]

BMC Nephrol
Aykut H, Alışır Ecder S, Ecder T.
europepmc   +1 more source

SAR-Guided Scaffold Innovation of Selective V₂R Antagonists: Therapeutic Frontiers in ADPKD. [PDF]

ACS Med Chem Lett
Shi H, Li Y, Liang SH.
europepmc   +1 more source

Real-World Outcomes of Sodium-Glucose Cotransporter 2 Inhibitor Therapy in Nondiabetic Autosomal-Dominant Polycystic Kidney Disease: Effects on Progression to Dialysis in a TrinetX Cohort. [PDF]

Mayo Clin Proc Innov Qual Outcomes
Chang CH, Kuo YC, Kuan YH, Lim PS, Chung MC, Pan YR, Luo CW, Wu TK.   +7 more
europepmc   +1 more source